Literature DB >> 22630814

Human complement C3 is a substrate for transglutaminases. A functional link between non-protease-based members of the coagulation and complement cascades.

Camilla Lund Nikolajsen1, Carsten Scavenius, Jan J Enghild.   

Abstract

In this study, we report the finding of functional cross-talk between two non-protease components of the complement and coagulation cascades. We show that complement C3, a central component of the complement system, is associated with the fibrin clot and that C3 becomes covalently cross-linked to other proteins during coagulation. Enzymatic incorporation of dansylcadaverine and dansyl-PGGQQIV into C3 by coagulation factor XIIIa and tissue transglutaminase demonstrated that C3 is a transglutaminase substrate. This suggested that coagulation factor XIIIa covalently cross-links C3 to clot components during coagulation. Using mass spectrometry, we verified that C3 indeed is covalently associated with the fibrin clot in a ratio of 0.05:1 relative to the known coagulation factor XIIIa substrate α2-antiplasmin.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22630814     DOI: 10.1021/bi3004022

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  5 in total

1.  Coagulation factor XIIIa substrates in human plasma: identification and incorporation into the clot.

Authors:  Camilla Lund Nikolajsen; Thomas F Dyrlund; Ebbe Toftgaard Poulsen; Jan J Enghild; Carsten Scavenius
Journal:  J Biol Chem       Date:  2014-01-17       Impact factor: 5.157

2.  Evaluation of follicular synchronization caused by estrogen administration and its reproductive outcome.

Authors:  Bi Wu; Yan Shi; Xia Gong; Lin Yu; Qiuju Chen; Jian Wang; Zhaogui Sun
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

3.  Identification of transglutaminase reactive residues in human osteopontin and their role in polymerization.

Authors:  Brian Christensen; Elias D Zachariae; Carsten Scavenius; Morten Thybo; Morten M Callesen; Søren Kløverpris; Claus Oxvig; Jan J Enghild; Esben S Sørensen
Journal:  PLoS One       Date:  2014-11-24       Impact factor: 3.240

Review 4.  Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk.

Authors:  Katherine Kearney; Darren Tomlinson; Kerrie Smith; Ramzi Ajjan
Journal:  Cardiovasc Diabetol       Date:  2017-03-09       Impact factor: 9.951

Review 5.  Fibrinogen and Antifibrinolytic Proteins: Interactions and Future Therapeutics.

Authors:  Nikoletta Pechlivani; Katherine J Kearney; Ramzi A Ajjan
Journal:  Int J Mol Sci       Date:  2021-11-21       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.